• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点阻断在转移性尿路上皮癌中的应用。

Immune Checkpoint Blockade in Metastatic Urothelial Cancer.

机构信息

Arjun Vasant Balar, New York University, New York, NY.

出版信息

J Clin Oncol. 2017 Jul 1;35(19):2109-2112. doi: 10.1200/JCO.2017.72.8444. Epub 2017 May 8.

DOI:10.1200/JCO.2017.72.8444
PMID:28481707
Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 62-year-old man with a 45 pack per year tobacco-smoking history presented with painless gross hematuria in the fall of 2015 and was ultimately diagnosed with muscle-invasive urothelial bladder cancer. He received four cycles of cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy with pelvic lymph node dissection, which disclosed residual high-grade muscle-invasive urothelial cancer extending to the perivesical fat and involving two of 20 pelvic lymph nodes (pT3N2). Six months later, surveillance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic mass with possible rectal wall invasion consistent with locally recurrent and metastatic urothelial cancer. Although feeling generally well, he reported having had progressive constipation, pelvic pressure, and narrow-caliber stools for 2 months. He was seen in consultation for management of recurrent bladder cancer.

摘要

肿瘤学大查房系列旨在将发表在《临床肿瘤学杂志》上的原始报告置于临床背景下。病例介绍后,将描述诊断和治疗挑战,回顾相关文献,并总结作者建议的治疗方法。本系列的目标是帮助读者更好地理解如何将关键研究的结果(包括发表在《临床肿瘤学杂志》上的研究结果)应用于他们自己临床实践中看到的患者。一位 62 岁男性,有 45 包/年的吸烟史,于 2015 年秋季出现无痛性肉眼血尿,最终被诊断为肌层浸润性膀胱尿路上皮癌。他接受了四个周期的顺铂为基础的新辅助化疗,随后进行根治性膀胱切除术和盆腔淋巴结清扫术,结果显示残留的高级别肌层浸润性尿路上皮癌累及膀胱周围脂肪和 20 个盆腔淋巴结中的 2 个(pT3N2)。6 个月后,监测影像学检查发现新的腹膜后淋巴结肿大和右侧骨盆大肿块,可能侵犯直肠壁,符合局部复发性和转移性尿路上皮癌。尽管他一般感觉良好,但他报告说已经有 2 个月的进行性便秘、骨盆压迫和细便。他因复发性膀胱癌就诊。

相似文献

1
Immune Checkpoint Blockade in Metastatic Urothelial Cancer.免疫检查点阻断在转移性尿路上皮癌中的应用。
J Clin Oncol. 2017 Jul 1;35(19):2109-2112. doi: 10.1200/JCO.2017.72.8444. Epub 2017 May 8.
2
Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress.转移性尿路上皮癌的靶向治疗:进展中。
J Clin Oncol. 2016 Jun 20;34(18):2088-92. doi: 10.1200/JCO.2016.67.1420. Epub 2016 May 9.
3
Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?肌层浸润性膀胱癌的化疗:晚做总比不做好?
J Clin Oncol. 2016 Mar 10;34(8):780-5. doi: 10.1200/JCO.2015.65.4442. Epub 2016 Jan 19.
4
Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?原发膀胱癌转移背景下的确定性治疗:何人、如何、何时以及为何?
J Clin Oncol. 2016 Oct 10;34(29):3495-3498. doi: 10.1200/JCO.2016.68.3714.
5
Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragonadal Germ Cell Tumors.数据匮乏环境下的决策制定:睾丸和性腺外生殖细胞肿瘤脑转移的管理。
J Clin Oncol. 2016 Feb 1;34(4):303-6. doi: 10.1200/JCO.2015.64.0110. Epub 2015 Dec 14.
6
Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.浸润性尿路上皮癌的辅助化疗:甲氨蝶呤、长春新碱、顺铂、环磷酰胺、阿霉素和博来霉素(MVP-CAB)方案的经验:初步报告
Jpn J Clin Oncol. 1993 Oct;23(5):291-8.
7
Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer?时机至关重要:直肠癌放化疗后多久进行手术最佳?
J Clin Oncol. 2016 Nov 1;34(31):3724-3728. doi: 10.1200/JCO.2016.68.3698.
8
Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.脉管浸润、输尿管再植和膀胱癌病史与盆腔淋巴结阴性的肌层浸润性膀胱癌行部分膀胱切除术的不良预后相关。
Eur J Surg Oncol. 2013 Oct;39(10):1150-6. doi: 10.1016/j.ejso.2013.04.006. Epub 2013 May 27.
9
Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?抗程序性死亡-1 治疗在晚期黑色素瘤中的持续时间:足够好的东西有多少?
J Clin Oncol. 2018 Jun 10;36(17):1649-1653. doi: 10.1200/JCO.2017.76.8275. Epub 2018 Feb 1.
10
Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.不能手术的局部晚期非小细胞肺癌的同期放化疗。
J Clin Oncol. 2017 Jan;35(1):6-10. doi: 10.1200/JCO.2016.69.9678. Epub 2016 Nov 21.

引用本文的文献

1
Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.整合单细胞 RNA 测序以识别基于成纤维细胞的分子亚型,用于预测膀胱癌的预后和治疗反应。
Aging (Albany NY). 2024 Jul 18;16(14):11385-11408. doi: 10.18632/aging.206021.
2
The identification of a N-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.鉴定 N6-甲基腺苷修饰的免疫模式,以预测尿路上皮癌的免疫治疗反应和生存。
Aging (Albany NY). 2024 May 1;16(9):7774-7798. doi: 10.18632/aging.205782.
3
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
durvalumab 治疗卡介苗(BCG)无应答性膀胱尿路上皮原位癌的 II 期研究。
Clin Cancer Res. 2023 Oct 2;29(19):3875-3881. doi: 10.1158/1078-0432.CCR-23-0354.
4
IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.IGFBP7 与肿瘤免疫景观:膀胱癌免疫治疗的新靶点。
Front Immunol. 2022 Jun 23;13:898493. doi: 10.3389/fimmu.2022.898493. eCollection 2022.
5
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.利用溶瘤病毒激发膀胱癌的肿瘤免疫微环境。
Nat Rev Urol. 2021 Sep;18(9):543-555. doi: 10.1038/s41585-021-00483-z. Epub 2021 Jun 28.
6
Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.肿瘤微环境分析确定了与膀胱癌预后及肿瘤免疫治疗反应相关的亚型。
Front Genet. 2021 Mar 1;12:551605. doi: 10.3389/fgene.2021.551605. eCollection 2021.
7
Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer.以三联疗法作为非器官局限性膀胱癌主要治疗方法的生存结果评估
Front Oncol. 2019 Dec 6;9:1315. doi: 10.3389/fonc.2019.01315. eCollection 2019.
8
Update on the Treatment of Metastatic Urothelial Carcinoma.转移性尿路上皮癌的治疗进展
ScientificWorldJournal. 2018 Jun 6;2018:5682078. doi: 10.1155/2018/5682078. eCollection 2018.
9
Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review.根治性膀胱切除术在非器官局限性膀胱癌中的作用:一项系统评价。
Bladder Cancer. 2018 Jan 20;4(1):31-40. doi: 10.3233/BLC-170130.